Oncolytic myxoma virus: The path to clinic

Highlights • MYXV is a candidate oncolytic virus with varying efficacies of oncolytic properties. • MYXV productively infects many classes of human cancer cells. • MYXV discriminates cancerous human myeloid cells from the normal CD34+ stem cells. • MYXV is an attractive ex vivo purging agent candida...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-09, Vol.31 (39), p.4252-4258
Hauptverfasser:	Chan, Winnie M, Rahman, Masmudur M, McFadden, Grant
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology animal ovaries Animals Antigen (tumor-associated) antigens Bone marrow clinical trials Clinical Trials as Topic Genes Hematological malignancies host range Humans immune response Immunotherapy Leukemia Medical research Melanoma Models, Animal Myxoma virus Myxoma virus - immunology Myxoma virus - pathogenicity Neoplasms - therapy Oncolytic Virotherapy Oncolytic Viruses - pathogenicity Oncolytic Viruses - physiology Ovarian cancer ovarian neoplasms Pancreatic cancer pancreatic neoplasms patients Poxviridae rabbits Rabbits - virology therapeutics vaccines viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • MYXV is a candidate oncolytic virus with varying efficacies of oncolytic properties. • MYXV productively infects many classes of human cancer cells. • MYXV discriminates cancerous human myeloid cells from the normal CD34+ stem cells. • MYXV is an attractive ex vivo purging agent candidate for hematological malignancies. • MYXV possesses significant oncolytic potential for pancreatic cancer and gliomas.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.05.056